Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Pancreatic Neoplasms 84Carcinoma, Non-Small-Cell Lung 56Triple Negative Breast Neoplasms 35Breast Neoplasms 34Neoplasms 28Neoplasm Metastasis 28Colorectal Neoplasms 17Lung Neoplasms 13Carcinoma, Pancreatic Ductal 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Adenocarcinoma 9Stomach Neoplasms 8Melanoma 8Carcinoma 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms by Site 6Fallopian Tube Neoplasms 6Small Cell Lung Carcinoma 5Carcinoma, Squamous Cell 5Peritoneal Neoplasms 4Head and Neck Neoplasms 4Digestive System Neoplasms 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Solid Tumor 3Sarcoma 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Histologic Type 3

Interventions

pembrolizumab 2Docetaxel 2Cisplatin 2Bevacizumab 2130-nm albumin-bound paclitaxel 2taxane 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Sorafenib 1Pemetrexed 1Paclitaxel 1Nivolumab 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Drug Therapy 1Biosimilar Pharmaceuticals 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Vaccinia × 130-nm albumin-bound paclitaxel × Clear all
NCT06463665 2026-06-04

VIRO-25

Genelux Corporation

Phase 2 Recruiting
142 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡